People with HIV may benefit from earlier lung cancer screening

Subhashini Sellers at CROI 2019. Photo by Liz Highleyman.
Liz Highleyman
Published: 12 March 2019

People living with HIV, especially women, may develop lung cancer at an earlier age and with a less extensive smoking history than people in the general population, according to a study presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2019) last week in Seattle. These findings suggest that lung cancer screening guidelines like those in the United States may miss many HIV-positive people who could benefit from earlier detection and treatment.

"People with HIV may not be adequately captured by current screening recommendations," Dr Subhashini Sellers of the University of North Carolina at Chapel Hill told conference attendees.

As people with HIV live longer thanks to effective antiretroviral treatment, non-communicable diseases such as cancer and cardiovascular disease account for a growing proportion of deaths.

Lung cancer – the leading cause of cancer-related death worldwide – is one of several non-AIDS malignancies that occurs at a higher rate in people living with HIV. In addition, people with HIV are diagnosed with lung cancer at an earlier age on average and have worse outcomes including shorter survival, Sellers said. HIV-positive people are more likely to smoke than their HIV-negative counterparts, but immune system impairment and other HIV-related factors may also contribute to this disparity.

Lung cancer often does not cause symptoms at early stages and many people are diagnosed late, when it is more difficult to treat. The National Lung Screening Trial, which enrolled more than 53,000 current and former heavy smokers in the United States, found that people who received annual low-dose computerised tomography (CT) scans had a 20% lower risk of lung cancer death.

The United States Preventive Services Task Force (USPSTF) recommends annual CT screening for people age 55 to 80 with a cumulative smoking history of at least 30 pack-years, who either still smoke or have quit within the past 15 years. Nonetheless, a recent study showed that the vast majority of current and former heavy smokers do not receive regular screening.

Current UK guidelines do not recommend lung cancer screening and it is not routinely offered through the National Health Service.

Sellers and colleagues evaluated whether the criteria used in the National Lung Screening Trial – which excluded HIV-positive people – are adequate to identify lung cancer in men and women living with HIV. They also looked at whether alternative thresholds might improve lung cancer detection rates in this population

The analysis included all people with confirmed lung cancer who were age 40 or older and current or former smokers in two large observational cohorts, the Women’s Interagency HIV Study (WIHS) and the Multicenter AIDS Cohort Study (MACS). They were matched with similar HIV-positive control subjects without lung cancer from the same cohort.

Sellers reported that 44 women in WIHS and 17 men in MACS were diagnosed with lung cancer during the study period. Lung cancer incidence was 270 per 100,000 person-years among women and 104 per 100,000 person-years among men, a significant difference. These findings mirror trends in the general population, with stable incidence among women and decreasing levels among men, she said.

Women with lung cancer had a significantly lower median CD4 cell count than control subjects without lung cancer (348 vs 452, respectively); the difference in viral load did not reach statistical significance. Among the men, neither the difference in CD4 count (387 vs 549, respectively) nor viral load was significant.

Women with and without lung cancer were about equally likely to still smoke (61% vs 59%) and to have a smoking history of 30 pack-years or more (30% vs 20%, not a significant difference); however, those with lung cancer were nearly twice as likely to have quit 15 or fewer years ago (93% vs 56%). Among men, those with lung cancer were much more likely to still smoke and to have at least a 30 pack-year history (71% vs 24% for both), but in both groups nearly all who quit had done so within the past 15 years.

The researchers found that only 16% of women and 24% of men diagnosed with lung cancer met the USPSTF screening criteria.

For HIV-positive women, decreasing the age threshold, amount of time since smoking cessation ('quit time') or number of pack-years – while holding the other two variables steady – all increased sensitivity, or ability of the criteria to accurately identify those with lung cancer. In men, lowering the screening age from 55 to 40 made the biggest difference. Adding low CD4 count or an AIDS diagnosis did not further improve the performance of the criteria.

The researchers determined that the optimal criteria for HIV-positive women would be to start screening at age 49 with a smoking history of 16 or more pack-years and a quit time of 15 years (52% sensitivity; 75% specificity). For HIV-positive men, the optimal criteria would be age 43 with a smoking history of more than 19 pack-years and a quit time of 15 years (82% sensitivity; 76% specificity). That is, these findings suggest that the smoking threshold for screening should be halved for women and reduced by a third for men living with HIV.

"Current USPSTF lung cancer screening guidelines performed poorly in people living with HIV," the researchers concluded. "Alternative thresholds of younger age and decreased pack year history and quit date can better identify people living with HIV to screen for lung cancer."

Reference

Sellers SA et al. Optimal lung cancer screening criteria among persons living with HIV. Conference on Retroviruses and Opportunistic Infections, Boston, abstract 15, 2019.

View the abstract on the conference website.

Watch the webcast of this presentation on the conference website.

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.